IP Library Granted Patent US 12,031,168
Granted Patent B2
US 12,031,168 · App. 17/116,353 · Granted Jul 9, 2024

Methods for controlling protease production

Inventors: Marja Paloheimo (Rajamäki, FI); Susanna Mäkinen (Rajamäki, FI); Peter Punt (Zeist, NL); Kari Juntunen (Rajamäki, FI); Terhi Puranen (Rajamäki, FI); Jari Vehmaanperä (Rajamäki, FI)
Assignee: ROAL OY
C12P21/02C07K14/37C07K16/14C12N9/0061C12N9/2405C12N9/2437C12N9/48C12N15/80C12Y110/03002C12Y302/01004
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,031,168
App. No.
17/116,353
Granted
Jul 9, 2024
Kind
B2
Abstract

The present description is related to the field of protein production. It introduces novel host cells with low protease activity, a novel protease regulator, its use in expression systems and protein production, and a method of producing host cells for protein production.

Claims (14)

1. A protein preparation comprising spent culture broth from production of a heterologous recombinant protein of interest in a host cell having at least one inactivated chromosomal gene wherein:

the at least one inactivated chromosomal gene comprises a nucleic acid sequence encoding a polypeptide comprising a sequence having at least 90% sequence identity with the amino acids 402-533 of SEQ ID NO: 13;

the at least one inactivated chromosomal gene is inactivated by disruption;

and the host cell has reduced protease activity on the heterologous recombinant protein of interest in the host cell compared to protease activity on the heterologous recombinant protein of interest in the host cell without said inactivation, and wherein the spent culture broth has a reduced amount of endogenous proteases compared to a corresponding spent culture broth produced in a host cell with an intact nucleic acid sequence encoding a polypeptide comprising a sequence having at least 90% sequence identity with the amino acids 402-533 of SEQ ID NO: 13;

and wherein the heterologous recombinant protein of interest has an increased stability in the spent culture broth compared to a protein preparation produced in the same host cell without said inactivation.

2. The protein preparation of claim 1 , wherein the protein preparation further comprises at least one further component selected from stabilizer, preservative, fragrant, buffer, salt, and colorant.

3. The protein preparation of claim 1 , wherein the protein preparation has an improved protein stability compared to a corresponding protein preparation produced in a host cell with an intact nucleic acid sequence encoding a polypeptide comprising a sequence having at least 90% sequence identity with the amino acids 402-533 of SEQ ID NO: 13.

4. The protein preparation of claim 2 , wherein the protein preparation has an improved protein stability compared to a corresponding protein preparation produced in a host cell with an intact nucleic acid sequence encoding a polypeptide comprising a sequence having at least 90% sequence identity with the amino acids 402-533 of SEQ ID NO: 13.

5. The protein preparation of claim 1 , wherein the protein preparation further comprises at least one recombinant protein produced by the host cell and selected from a pharmacologically active protein, antibody, antibody fragment, therapeutic protein, biosimilar, multi-domain protein, peptide hormone, antimicrobial peptide, peptide, carbohydrate binding module, enzyme, cellulase, protease, protease inhibitor, aminopeptidase, amylase, carbohydrase, carboxypeptidase, catalase, chitinase, cutinase, deoxyribonuclease, esterase, alpha-galactosidase, beta-galactosidase, glucoamylase, alpha-glucosidase, beta-glucosidase, invertase, laccase, lipase, mannanase, mutanase, oxidase, pectinolytic enzyme, peroxidase, phospholipase, phytase, phosphatase, polyphenoloxidase, redox enzyme, proteolytic enzyme, ribonuclease, transglutaminase, and xylanase.

6. The protein preparation of claim 2 , wherein the protein preparation further comprises at least one recombinant protein produced by the host cell and selected from a pharmacologically active protein, antibody, antibody fragment, therapeutic protein, biosimilar, multi-domain protein, peptide hormone, antimicrobial peptide, peptide, carbohydrate binding module, enzyme, cellulase, protease, protease inhibitor, aminopeptidase, amylase, carbohydrase, carboxypeptidase, catalase, chitinase, cutinase, deoxyribonuclease, esterase, alpha-galactosidase, beta-galactosidase, glucoamylase, alpha-glucosidase, beta-glucosidase, invertase, laccase, lipase, mannanase, mutanase, oxidase, pectinolytic enzyme, peroxidase, phospholipase, phytase, phosphatase, polyphenoloxidase, redox enzyme, proteolytic enzyme, ribonuclease, transglutaminase, and xylanase.

7. The protein preparation of claim 3 , wherein the protein preparation further comprises at least one recombinant protein produced by the host cell and selected from a pharmacologically active protein, antibody, antibody fragment, therapeutic protein, biosimilar, multi-domain protein, peptide hormone, antimicrobial peptide, peptide, carbohydrate binding module, enzyme, cellulase, protease, protease inhibitor, aminopeptidase, amylase, carbohydrase, carboxypeptidase, catalase, chitinase, cutinase, deoxyribonuclease, esterase, alpha-galactosidase, beta-galactosidase, glucoamylase, alpha-glucosidase, beta-glucosidase, invertase, laccase, lipase, mannanase, mutanase, oxidase, pectinolytic enzyme, peroxidase, phospholipase, phytase, phosphatase, polyphenoloxidase, redox enzyme, proteolytic enzyme, ribonuclease, transglutaminase, and xylanase.

8. The protein preparation of claim 4 , wherein the protein preparation further comprises at least one recombinant protein produced by the host cell and selected from a pharmacologically active protein, antibody, antibody fragment, therapeutic protein, biosimilar, multi-domain protein, peptide hormone, antimicrobial peptide, peptide, carbohydrate binding module, enzyme, cellulase, protease, protease inhibitor, aminopeptidase, amylase, carbohydrase, carboxypeptidase, catalase, chitinase, cutinase, deoxyribonuclease, esterase, alpha-galactosidase, beta-galactosidase, glucoamylase, alpha-glucosidase, beta-glucosidase, invertase, laccase, lipase, mannanase, mutanase, oxidase, pectinolytic enzyme, peroxidase, phospholipase, phytase, phosphatase, polyphenoloxidase, redox enzyme, proteolytic enzyme, ribonuclease, transglutaminase, and xylanase.

9. The protein preparation of claim 1 , wherein the protein preparation further comprises at least one recombinant protein produced by the host cell and selected from a pharmacologically active protein, antibody, antibody fragment, therapeutic protein, biosimilar, multi-domain protein, peptide hormone, antimicrobial peptide, peptide, carbohydrate binding module, enzyme, cellulase, protease, protease inhibitor, aminopeptidase, amylase, carbohydrase, carboxypeptidase, catalase, chitinase, cutinase, deoxyribonuclease, esterase, alpha-galactosidase, beta-galactosidase, glucoamylase, alpha-glucosidase, beta-glucosidase, invertase, laccase, lipase, mannanase, mutanase, oxidase, pectinolytic enzyme, peroxidase, phospholipase, phytase, phosphatase, polyphenoloxidase, redox enzyme, proteolytic enzyme, ribonuclease, transglutaminase, and xylanase.

10. The protein preparation of claim 5 , wherein the heterologous recombinant protein has improved protein authenticity compared to a corresponding protein preparation produced in a host cell with an intact nucleic acid sequence encoding a polypeptide comprising a sequence having at least 90% sequence identity with the amino acids 402-533 of SEQ ID NO: 13.

Assignments (2)
CHANGE OF NAME Recorded Aug 18, 2025
From: ROAL OY
To: AB ENZYMES FINLAND OY
Reel/Frame 072042/0201 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 9, 2020
From: PALOHEIMO, MARJA; MAKINEN, SUSANNA; PUNT, PETER; JUNTUNEN, KARI; PURANEN, TERHI; VEHMAANPERA, JARI
To: ROAL OY
Reel/Frame 054594/0617 →
Priority Claims (1)
FI 20155112 · Feb 20, 2015 · national
Continuity (2)
Continuation 15552387
Related Publication 20210102231A1 · Apr 8, 2021